Related Experiment Videos
Clinical variability of type II sialidosis by C808T mutation
G Rodríguez Criado1, A V Pshezhetsky, A Rodríguez Becerra
1Unidad de Dismorfología, Hospital Universitario Virgen del Rocío, Seville, Spain.
American Journal of Medical Genetics. Part A
|January 11, 2003
Summary
Sialidosis, a genetic disorder, arises from NEU gene mutations causing enzyme deficiency and substrate buildup. A specific mutation (C808T) was identified in three Spanish patients, suggesting a founder effect.
Area of Science:
- Genetics
- Biochemistry
- Lysosomal Storage Disorders
Background:
- Sialidosis is an autosomal recessive lysosomal storage disorder.
- It results from mutations in the NEU gene, leading to alpha-N-acetyl neuraminidase (sialidase) deficiency.
- This deficiency causes the accumulation of sialylated substrates in lysosomes.
Observation:
- This report details three patients diagnosed with type II sialidosis.
- Clinical presentations varied, including classic infantile and congenital forms, with one patient exhibiting borderline cognitive delay.
- All patients shared the C808T homozygous mutation in the NEU gene.
Findings:
- The C808T mutation in the NEU gene is strongly associated with sialidosis in these patients.
- The geographic origin of the patients' ancestors from the Seville region of Spain suggests a potential founder mutation.
- Genetic analysis confirmed homozygous C808T mutation across all three unrelated individuals.
Implications:
- Identification of the Seville founder mutation can aid in genetic counseling and carrier screening.
- Understanding the genetic basis of sialidosis is crucial for developing targeted therapies.
- This finding highlights the importance of investigating founder effects in rare genetic disorders.